Regeneron Pharmaceuticals, Inc. (REGN) on Monday said that it has entered into a strategic in-licensing agreement with China’s Hansoh Pharmaceuticals Group Company to acquire exclusive clinical ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in combination with Novo Nordisk's popular obesity drug Wegovy in a mid-stage ...

TARRYTOWN, N.Y. - Regeneron Pharmaceuticals ... exclusive rights for the clinical development and commercialization of a new obesity drug candidate outside of China. The deal, announced Monday, ...

Regeneron Pharmaceuticals has announced that it will be gaining rights to Hansoh Pharmaceuticals’ investigational dual GLP-1/GIP receptor agonist in a deal worth $2bn. The in-licensing agreement will ...

The race to develop muscle-preserving treatments alongside popular obesity drugs like Eli Lillys (NYSE:LLY) Zepbound and Novo ...

Regeneron inks $80 million deal with Hansoh for Phase 3 obesity trial, with up to $1.93 billion in milestone payouts. See how Matt Maley is positioning for post-Fed volatility and momentum—live ...

The company recently entered into an in-licensing agreement for an obesity drug with Hansoh Pharmaceuticals ... More on REGN’s Deal With Hansoh Pharma Regeneron will acquire exclusive clinical ...

TARRYTOWN, N.Y. - Regeneron Pharmaceuticals ... development and commercialization of a new obesity drug candidate outside of China. The deal, announced Monday, revolves around HS-20094, a GLP ...

Regeneron also said it will license an experimental obesity drug from China's Hansoh Pharmaceuticals (3692.HK), opens new tab in a deal worth up to $2.01 billion. Weight-loss drugs from current ...